Cost-effectiveness of a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care

被引:35
|
作者
Turner, D. A. [1 ]
Paul, S. [2 ]
Stone, M. A. [3 ]
Juarez-Garcia, A. [4 ]
Squire, I. [5 ]
Khunti, K. [3 ]
机构
[1] Univ Southampton, Wessex Inst Hlth Res & Dev, Southampton SO16 7PX, Hants, England
[2] Oxford Ctr Diabet Endocrinol & Metab, Diabet Trials Unit, Oxford, England
[3] Univ Leicester, Dept Hlth Sci, Div Gen Practice & PHC, Leicester, Leics, England
[4] Univ Birmingham, Hlth Serv Management Ctr, Birmingham B15 2TT, W Midlands, England
[5] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England
关键词
D O I
10.1136/hrt.2007.125708
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To determine if a disease management programme for patients with coronary heart disease and heart failure represents an efficient use of health services resources. Methods: We carried out an economic evaluation alongside a cluster randomised control trial of 1163 patients with coronary heart disease and chronic heart failure in 20 primary care practices in the United Kingdom. Practices were randomised to either a control group, where patients received standard general practice care, or an intervention group where patients had access to a specialist nurse-led disease management programme. We estimated costs in both groups for coronary heart disease-related resource use. The main outcome measure used in the economic evaluation was quality adjusted life years (QALY) measured using the EuroQol. Results: The disease management programme was associated with an increase in the QALY measured of 0.03 per year and an increase in the total NHS costs of 425 pound ((sic)540), of this only 83 pound was directly associated with the provision of the nurse clinics. The clinics generated additional QALY at an incremental cost of 13 pound 158 per QALY compared to the control group. Conclusions: The use of a nurse-led disease management programme is associated with increased costs in other coronary heart disease-related services as well as for the costs of the clinics. They are also associated with improvements in health. Even in the short term these disease management programmes may represent a cost-effective service, as additional QALY are generated at an acceptable extra cost.
引用
收藏
页码:1601 / 1606
页数:6
相关论文
共 50 条
  • [31] Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.
    Gaspoz, J
    Coxson, PG
    Goldman, PA
    Williams, LW
    Kuntz, KM
    Hunink, MGM
    Goldman, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (23): : 1800 - 1806
  • [32] Secondary prevention in coronary heart disease - Payment for chronic disease management should include coronary heart disease
    Bethell, HJN
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1998, 317 (7172): : 1592 - 1592
  • [33] COST-EFFECTIVENESS OF ANTIHYPERLIPEMIC THERAPY IN THE PREVENTION OF CORONARY HEART-DISEASE - THE CASE OF CHOLESTYRAMINE
    OSTER, G
    EPSTEIN, AM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 258 (17): : 2381 - 2387
  • [34] Prevention of coronary heart disease with aspirin and clopidogrel: efficacy, safety, costs and cost-effectiveness
    Ho, WK
    Hankey, GJ
    Eikelboom, JW
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (03) : 493 - 503
  • [35] Cost-effectiveness analysis of rheumatic heart disease prevention strategies
    Manji, Rizwan A.
    Witt, Julia
    Tappia, Paramjit S.
    Jung, Young
    Menkis, Alan H.
    Ramjiawan, Bram
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2013, 13 (06) : 715 - 724
  • [36] From efficacy to effectiveness in the secondary prevention of coronary heart disease
    Cuixart, CB
    [J]. REVISTA ESPANOLA DE CARDIOLOGIA, 2004, 57 (11): : 1007 - 1008
  • [37] Cost-effectiveness of rosuvastatin in the prevention of ischemic heart disease in Portugal
    Pinto, Carlos Gouveia
    Carrageta, Manuel Oliveira
    Miguel, Luis Silva
    [J]. VALUE IN HEALTH, 2008, 11 (02) : 154 - 159
  • [38] Cost-effectiveness of Rosuvastatin in the prevention of ischemic heart disease in Portugal
    Gouveia-Pinto, C
    Carrageta, M
    Silva-Miguel, L
    [J]. VALUE IN HEALTH, 2005, 8 (06) : A102 - A102
  • [39] Cost Effectiveness of Coronary Heart Disease Prevention Strategies in Adults
    Adalsteinn D. Brown
    Alan M. Garber
    [J]. PharmacoEconomics, 1998, 14 : 27 - 48
  • [40] Cost effectiveness of coronary heart disease prevention strategies in adults
    Brown, AD
    Garber, AM
    [J]. PHARMACOECONOMICS, 1998, 14 (01) : 27 - 48